Alzheimer's Drug Discovery Foundation

Alzheimer's Drug Discovery Foundation
Name	Alzheimer's Drug Discovery Foundation
Formation	1998
Founder	Leonard Lauder; Ronald S. Lauder
Type	Nonprofit organization
Headquarters	New York City
Focus	Alzheimer disease research; neurodegenerative disorders

Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation (ADDF) is a nonprofit biomedical organization focused on accelerating drug discovery and development for Alzheimer's disease, Parkinson's disease, Huntington's disease, and related Lewy body dementias. It funds preclinical and early-stage clinical programs, supports translational science, and partners with academic institutions, pharmaceutical companies, and philanthropic organizations to move therapeutics toward regulatory milestones such as approvals by the Food and Drug Administration and approvals elsewhere like the European Medicines Agency. The foundation operates in the context of major biomedical actors including the National Institutes of Health, the Alzheimer's Association, and leading research centers such as Massachusetts General Hospital, Johns Hopkins University, and Columbia University.

Overview

ADDF functions at the interface of basic neuroscience, medicinal chemistry, and clinical development, supporting work in amyloid-beta, tau, neuroinflammation, synaptic health, and metabolic contributors to disease. Its activities intersect with stakeholders such as the Biotechnology Innovation Organization, multinational firms like Pfizer, Roche, and Eli Lilly and Company, and venture capital groups exemplified by Flagship Pioneering and ARCH Venture Partners. Programs emphasize translational pipelines linking laboratories at institutions such as Stanford University, Harvard University, University of California, San Francisco, University of Pennsylvania, and University College London to contract research organizations and incubators like Cambridge Innovation Center.

History and Founding

Founded in 1998 by philanthropists Leonard Lauder and Ronald S. Lauder, ADDF emerged amid heightened public interest driven by advocacy from groups including the Alzheimer's Association and legislative initiatives like the National Alzheimer’s Project Act. Early collaborations involved researchers from the Salk Institute, Scripps Research, and the Gladstone Institutes, and drew attention from policymakers in New York City and funding bodies such as the Gates Foundation and the Wellcome Trust. The foundation grew alongside landmark scientific developments, including discoveries at the Whitehead Institute, structural biology advances at the European Molecular Biology Laboratory, and clinical trial methodologies refined at centers such as Mayo Clinic and Cleveland Clinic.

Mission and Programs

ADDF’s mission centers on accelerating discovery for therapeutics by funding high‑risk, high‑reward projects that traditional funders or industry might not support. Program areas encompass small molecules, biologics, repurposing of approved drugs like those studied at Imperial College London and Mount Sinai Hospital, biomarker development involving groups such as Roche Diagnostics and Quanterix, and preclinical model innovation with contributions from the Allen Institute for Brain Science and the Jackson Laboratory. Training and career development programs engage investigators at Columbia University Irving Medical Center, Yale University, University of California, San Diego, and international hubs like Karolinska Institutet.

Research Funding and Grants

ADDF issues competitive grants, bridge funding, and milestone-driven awards to academic labs and startup ventures, collaborating with funders such as the Michael J. Fox Foundation for Parkinson's, the Simons Foundation, and corporate venture arms at Novartis and Johnson & Johnson. Grants have supported work on targets identified in studies published by groups at the Broad Institute, structural insights from Protein Data Bank entries, and pharmacology informed by consortia like the Alzheimer's Disease Neuroimaging Initiative. Awardees have included investigators from Oxford University, Cambridge University, The Rockefeller University, Duke University, and Northwestern University.

Partnerships and Collaborations

ADDF partners with international and domestic organizations, including the European Union research programs, the World Health Organization in policy dialogues, and biotech accelerators like IndieBio and Y Combinator. Strategic alliances extend to academia-industry consortia such as the Accelerating Medicines Partnership and collaborations with diagnostic developers like Abbott Laboratories and Siemens Healthineers. Public-private interactions have engaged regulatory science groups at the FDA and patient advocacy networks including UsAgainstAlzheimer's.

Impact and Notable Achievements

ADDF has helped advance numerous programs into clinical trials, supported biomarker validation efforts referenced by investigators at Massachusetts Institute of Technology and enabled repurposing studies originally carried out at National Institute on Aging labs. Notable achievements include funding early-stage projects that led to partnerships with companies such as Biogen, AC Immune, and Cassava Sciences; support for tau-targeting strategies pioneered in labs at University of California, Berkeley and University of Edinburgh; and backing of neuroinflammation research linked to investigators affiliated with Karolinska Institutet and McGill University. These interventions contributed to scientific outputs cited alongside work from the ClinicalTrials.gov registry and publications in journals like Nature Medicine, Science Translational Medicine, and The Lancet Neurology.

Governance and Funding Sources

Governance comprises a board with leaders from finance, academia, and philanthropy, connecting to networks involving the Council on Foreign Relations, family foundations like the Estée Lauder Companies, and philanthropic advisors active in New York and beyond. Funding sources include individual donors, family offices, foundations such as the Simons Foundation and Chan Zuckerberg Initiative, and corporate philanthropy from entities like Takeda Pharmaceutical Company and Amgen. ADDF also leverages partnerships with venture funds and government agencies including the NIH to co-fund translational milestones.

Category:Medical research foundations Category:Alzheimer's disease research